Janus Henderson Q1 2026 Preview: A $223B Growth Book Added Intuitive Surgical and Biotech Risk
Janus Henderson kept Nvidia and Microsoft on top in Q4 2025, but the more interesting signal was underneath: new exposure to Intuitive Surgical, Protagonist Therapeutics and other growth-healthcare names. The next filing will show whether that rotation keeps building.
JANUS HENDERSON GROUP PLC went into year-end with a portfolio that still looked unmistakably pro-growth. NVDA and MSFT remained huge in Q4 2025, and the overall filing stayed centered on large-cap tech. But the more interesting signal was the new healthcare and biotech rotation, led by ISRG and PTGX. With the next filing due on May 15, 2026, readers need to know whether Janus is broadening growth exposure or just trading around the edges.
TL;DR
- The top of the book still belonged to the AI leaders: NVDA and MSFT stayed dominant.
- The new idea set shifted: ISRG and PTGX were the most revealing fresh buys.
- Not every growth name gained weight: META was cut materially.
- The filing mixed scale and selectivity: Janus kept the mega-cap core while reaching for catalyst-driven healthcare names.
- Q1 watch: does that healthcare rotation deepen, or was it just a quarter-end rebalance?
JANUS HENDERSON GROUP PLC Top Holdings — 2025Q4 ($M)
Why This Filing Matters
Janus matters because it can show how traditional active growth managers are rebalancing inside an AI-led market. A book that keeps NVDA and MSFT large while adding ISRG and PTGX is not abandoning growth. It is diversifying the type of growth it wants to own.
Visible Signals In The Latest Filing
| Position | Value | Weight | Why it matters |
|---|---|---|---|
| NVDA | $15.39B | 7.16% | Nvidia remained the largest disclosed position, so Janus still leaned into the leaders of the AI cycle. |
| MSFT | $12.91B | 6.00% | Microsoft stayed a major core weight even after a modest trim. |
| ISRG | $897.4M | 0.42% | Intuitive Surgical was a major new add and an immediate signal that healthcare innovation was back on the radar. |
| PTGX | $231.4M | 0.11% | The Protagonist position shows Janus was willing to reach into smaller, catalyst-heavy biotech alongside the mega-caps. |
| META | $4.04B | 1.88% | The Meta cut matters because it funded new ideas without abandoning the growth playbook entirely. |
JANUS HENDERSON GROUP PLC Top 5 vs Rest Concentration — 2025Q4
What Q4 2025 Set Up
Q4 2025 looked like a two-speed portfolio. The top remained heavily concentrated in AI and platform winners. Underneath, new healthcare and biotech exposure appeared quickly enough to matter. That means the next Janus filing is less about whether it still likes tech and more about whether it wants a wider growth menu around that tech core.
JANUS HENDERSON GROUP PLC AUM History
Questions For Q1 2026
Does Intuitive Surgical stay big?
If ISRG remains substantial in Q1, Janus is likely building a durable healthcare-quality sleeve rather than taking a short-term trade.
Is the biotech exposure repeatable?
Another quarter of positions like PTGX would tell readers Janus wants more catalyst-driven risk under the hood.
Was the Meta trim an isolated source of funds?
If META keeps shrinking while healthcare builds, the portfolio rotation becomes much easier to call intentional.
Bottom Line
Janus Henderson’s next filing should be watched for breadth within growth. If the book still belongs to NVDA and MSFT but the healthcare and biotech positions keep growing, the manager will look like it is deliberately widening its growth exposure. If those new names fade, Q4 will look more tactical than thematic.
Q&A
When is Janus Henderson’s next 13F due?
Janus Henderson’s next 13F is due on May 15, 2026.
What were the most interesting new positions?
Intuitive Surgical and Protagonist Therapeutics were among the most interesting new positions in the Q4 2025 filing.
Why does the Meta trim matter?
Because it suggests Janus was willing to fund new growth-healthcare ideas by trimming an existing large-cap winner.
Related Research
Explore all researchAllianceBernstein kept Nvidia, Microsoft and Amazon on top in Q4 2025, but new exposure to Intuitive Surgical and aggressive increases in Netflix and ServiceNow made the next filing more interesting than another mega-cap recap. Here is what to watch.
Apr 17, 2026
Victory Capital kept mega-cap tech on top in Q4 2025, but the sharper signal was in the secondary moves: large increases in Netflix, Constellation Energy, TSMC and new positions like IQVIA. The next filing will show whether that diversification continues.
Apr 17, 2026
American Century’s Q4 2025 filing kept Nvidia and Microsoft on top, but the more revealing changes were the big Netflix increase, fresh utility and industrial additions, and a continued AI-heavy core. The next filing will show whether those side bets keep scaling.
Apr 17, 2026
AQR’s Q4 2025 filing kept expanding, with AUM rising to $190.63B, 69 new names, and a dramatic Bristol Myers build inside an already broad book. The next filing will show whether the quant giant keeps pressing this expansion or starts normalizing the roster again.
Apr 17, 2026
Nuveen’s Q4 2025 filing stayed large-cap and AI-heavy at the top, but the more revealing addition was a sizable fixed-income sleeve through NXUS and NHYB. The next filing will show whether those credit and bond ETFs remain central or fade back out.
Apr 17, 2026